1. Costanzi, J. J., Gagliano, R., Delaney, F., Harris, N., Thurman, G., Sakai, H., Goldstein, A., Loukas, D., Cohen, G., and Thomson, P. D., 1977, The effect of thymosin on patients with disseminated malignancies, Cancer
40:14–19.
2. David, J. R., 1975, Macrophage activation by lymphocyte mediators, Fed. Proc.
34:1730–1735.
3. Dumonde, D. C., Paradinas, F., Pulley, M., Southcott, B., O’Connell, D., Robinson M., and den Hollander, F., 1981, A histological study of intradermal and intralesional injection of human lymphoid cell line lymphokine (LCL-LK) in patients with advanced cancer, J. Clin. Hematol. Oncol.
11:130.
4. Dunn, P. A., Eaton, W. R., Lopatin, E., Tyrer, H., McEntire, J. E., Papermaster, B. W., Miller, A., and Vosika, G., 1982, Macrophage activation by lymphokine factors (MAF) as measured by phagocytosis, metabolic products, and tumor cell cytotoxicity: Correlation of multiparameter functional assays, in: Human Lymphokines: The Biological Immune Response Modifiers (A. Khan and N. O. Hill, eds.), pp. 67–82, Academic Press, New York.
5. Fidler, I. J., Darnell, J. H., and Budman, M. B., 1976, In vitro activation of mouse macrophage by rat lymphocyte mediators, J. Immunol.
117:666–673.